



A publication of the
**American
Pharmaceutical
Association**
and the
**American
Chemical
Society**



JOURNAL OF Pharmaceutical Sciences

June 1998

Volume 87, Number 6

MINIREVIEW

Current Perspectives on Pain upon Injection of Drugs

GAYLE A. BRAZEAU,^{*,†} BRIAN COOPER,[‡] KARI A. SVETIC,[†] CHARLES L. SMITH,[§] AND PRAMOD GUPTA^{||}

Contribution from *Department of Pharmaceutics, College of Pharmacy, Box 100494 JHMHC, Department of Oral and Maxillary Surgery and Diagnostic Sciences, College of Dentistry, Box 100416, Parker E. Mahan Facial Pain Center, College of Dentistry, Box 100437, JHMHC, University of Florida Gainesville, Florida 32610, and TAP Holdings, 2355 Waukegan Road, Deerfield, Illinois 60015.*

Received August 12, 1997. Final revised manuscript received March 12, 1998.
Accepted for publication March 16, 1998.

Abstract □ A limitation in the administration of parenteral products is the pain caused upon injection. Injection site pain has been predominately associated with intravenous, intramuscular, and subcutaneous administration. It becomes important for the formulation scientist to have a basic understanding of the physiology underlying the pain process, as well as the pharmaceutical factors associated with injection site pain. Initially, this review will provide the reader with a primer on the mediation of pain in the periphery and a compilation of those drugs that have been associated with pain on injection. In addition, this review will present important considerations and general formulation approaches or methods that have been used to overcome pain on injection. Finally, a brief overview of the various experimental systems used to investigate injection site pain is discussed.

Introduction

Pharmaceutical formulators are increasingly being asked to investigate the use of parenteral routes of drug administration. One likely explanation is the increasing interest in the therapeutic development and use of peptide or protein drugs and gene delivery, which due to their limited

oral bioavailability often require parenteral administration. Furthermore, the shift of patient care to the ambulatory setting has necessitated the investigation of the routes of drug administration that can be useful in the home health care environment for traditional small molecular weight molecules. Consequently, the formulator is often asked to provide successful short-term and/or long-term delivery of these therapeutic modalities, while maintaining stability and patient acceptability. The major routes of administration that have been utilized in preclinical and clinical trials are the intravenous, subcutaneous, and intramuscular routes of administration.¹ Other less commonly used routes include intraperitoneal, intrathecal, intracardiac, intracisternal, intralesional, intrapleural, intrauterine, and intradermal. However, these latter routes are frequently associated with specific drugs and therapies and limited to hospitalized patients.

From a formulator's perspective, the development of parenteral products requires optimization with respect to adequate stability, solubility, injectability, and tolerability of the therapeutic modality. The focus in the pharmaceutical literature, to date, has primarily been on understanding the factors and issues associated with developing formulations that achieve the requisite stability and solubility. It has also been critical to ensure the relative ease in the injectability of the product by minimizing viscosity or by providing guidelines on the safe route and rate of drug administration.

In contrast, pain or tissue damage upon injection of formulations (e.g., tolerability), while critical to the clinical (and even financial) success of these products, is less well understood by formulation scientists. The extent and

* Corresponding author. Phone: (352) 846-2724. Fax: (352) 392-4447. E-mail: brazeau@cop.health.ufl.edu.

[†] Department of Pharmaceutics, University of Florida.

[‡] Department of Oral and Maxillary Surgery and Diagnostic Sciences, University of Florida.

[§] Parker E. Mahan Facial Pain Center, University of Florida.

^{||} TAP Holdings.

mechanism of tissue irritation and/or damage following parenteral administration, as well as methods to minimize or eliminate these issues, have been discussed somewhat in the pharmaceutical literature.²⁻⁸ However, the underlying factors responsible for pain upon injection, which may occur without direct toxicity to the injected tissue, have not received as much attention by formulators in the development of new products. Possible explanations for the limited knowledge in understanding the extent and mechanisms of injection-associated pain include (1) the lack in the number and type of models available to study the physiology and mechanisms of pain, (2) the difficulty, variability, and cost associated with using animal models to evaluate pain, and (3) the necessity to use subjective versus objective measures (which often involve extensive experimental setups) to evaluate the extent of pain and/or methods to reduce pain either in animals or humans.

While it is critical to characterize the extent of *pain* upon injection during the development of parenteral formulations, these studies are often not conducted due to the limitations described above. In contrast, the screening of formulations for their potential to cause *tissue damage* (e.g., hemolysis, muscle damage) can be done relatively easily using experimental systems which are readily available, require a short time frame, and include the appropriate positive and negative controls.²⁻¹¹ The question to be raised at this point is whether there is a relationship between pain and tissue damage. Three types of relationships between pain and tissue damage are possible and need to be considered. First, it is possible that a given formulation can cause tissue damage that results in pain at the injection site. If this were the case, screening of formulations for their potential to cause tissue damage provides a reasonable first approach to rule out unacceptable formulations. Use of tissue toxicity screening methods can provide the formulator with a rational approach to develop and select the optimal formulations with respect to the desired physicochemical properties and tissue tolerability.

Second, in contrast, there may be drugs or formulations associated with pain upon injection where there is no indication of any type of tissue damage at the site of injection. This relationship is more problematic because it is possible that formulations that did not cause tissue damage in preclinical studies are now reported to cause pain on injection during the subsequent clinical trials. If volunteers and patients report moderate or severe pain with injection during clinical studies, this could potentially stop or limit further development of the product. It would be useful in this case to have methods to screen a parenteral formulation early during development for the potential to cause pain.

Finally, it is possible for a given formulation to cause tissue damage that is not associated with pain upon injection. The difficulty in this particular scenario may occur if the formulation requires repeated injections that could cause irreversible changes in the tissue at the site. It subsequently becomes the responsibility of those individuals involved in the preclinical and clinical trials for drugs designed for repeated administration to include in their experimental methods the assessment of the long-term impact of repeated administration on tissue at the injection site.

Since at this stage the formulator cannot be sure of the relationship between tissue damage and injection site pain, it is recommended that studies investigating the extent of pain and or tissue damage be included during the design of parenteral formulations. Furthermore, it becomes critical for the formulator to be aware of the physiology associated with pain and the factors that have been

reported to cause pain upon injection. The specific focus of this review will be to provide the formulator with (1) a basic primer to understanding the peripheral mediation of pain, (2) a discussion of those factors which have been reported to cause pain on injection, (3) a discussion of experimental systems to study pain on injection, (4) a report of those drugs reported to cause pain upon injection, and (5) a discussion on approaches which have been used to offset pain associated with injection. At this stage, there is no clear method that has been associated with a reduction of injection site pain.

For information on the specific methods to characterize the extent and mechanisms of *tissue damage* with parenteral administration, readers are referred to studies by Brazeau,^{2,3} Gupta,⁴ Comerski,⁵ Sutton,⁶⁻⁸ and Yalkowsky.⁹⁻¹¹

The Mediation of Pain by the Peripheral Nervous System

The anatomy and physiology of the pain system will be limited to a discussion of the peripheral nervous system, as it is this component that has principal bearing on the pain upon injection. Where appropriate, suggestions of possible mechanisms by which a parenteral formulation could interact with the pain system will be briefly discussed.

The sensation of pain is mediated in the periphery by multiple sets of specialized afferents (sensory fibers) called nociceptors. Like other sensory neurons, nociceptor cell bodies are found clustered in paired ganglia located within each spinal vertebra (see Figure 1). Each ganglion cell has a peripheral process (axon) that extends out to tissue (e.g., muscle) and a central process that travels into the spinal cord to communicate with the central nervous system. Nociceptors have been subclassified on both anatomic and functional bases. The diameter of the peripheral process (1–15 μm) and the presence or absence of a nonneuronal covering (myelin) determine the rate at which afferents conduct impulses (action potentials). This forms the basis for anatomic criteria by which afferents are classified. It was formerly believed that pain sensation derived solely from the small diameter, slowly conducting, thinly myelinated and unmyelinated subgroups (called $A\delta$ and C, respectively); however, recent evidence indicates that nociceptors are represented in all three major afferent categories. This includes the large diameter, fast conducting groups ($A\beta$), traditionally associated with touch sensation. It is worth noting that a parallel nomenclature is used for cutaneous ($A\beta$, $A\delta$, and C) and deep (muscle, viscera) afferents (group II, group III, and group IV). This distinction is mainly historical, as these classes are generally identical in function.¹²⁻¹⁶

While there is no absolute nomenclature for nociceptors, the most accepted naming system divides pain afferents according to their functional capacities. Therefore, nociceptors that respond to intense mechanical and thermal stimuli are mechanothermal nociceptors (MH). If they come from $A\delta$ or C fiber groups, they are called AMH and CMH, respectively.¹³ If they also have a chemical response, they are called polymodal nociceptors. Polymodal nociceptors are found in both myelinated and unmyelinated categories.^{17,18}

Nociceptors are usually silent at rest. That is, in the absence of intense stimuli there is no activity. However, some nociceptors of the C (or group IV) class maintain a slow continuous activity rate (usually <1 Hz). It is important to note that even when stimulated, nociceptor activity is possible in all classes without any sensation. That is because activity in a nociceptive ending will not




Figure 1—Innervation of tissue by peripheral afferents of the DRG. Pairs of dorsal root ganglia lie along the side of the spinal cord (left panel) and innervate peripheral tissues. Complimentary innervation of the head and oral tissues are supplied by paired trigeminal root ganglia. In the exploded section, innervation of muscle and skin are shown as relevant examples. Many thousands of cell bodies in each DRG contribute axons into peripheral nerves which have endings in all forms of peripheral tissue. Cell bodies for both nociceptive and non-nociceptive sensory afferents are found in the ganglia. Transduction (encoding) of sensory events occurs in the receptor ending (see Figure 2). The cell body synthesizes functional components of the neuron and ships them to both peripheral endings and to central synapses within the spinal cord.

necessarily be transmitted past the first relay in the spinal cord. Therefore, some critical level of activity is required before a sensation is reported. Once this critical frequency is achieved, the particular sensation is dependent upon the type of nociceptor activated. Different forms of sensation are associated with different subgroups. Activity in $A\beta$ or $A\delta$ nociceptors is associated with brief, intense burning (e.g., a match burn) or sharp, crushing or tearing sensations. Activity in C fiber nociceptors is associated with diffuse burning (e.g., sunburn) or aching sensations.^{19,20}

Nociceptors are distinguished from other afferent groups (those mediating touch, tickle, pressure, warmth, cold) by their transducing (or encoding) capacity. All sensory afferents have characteristic response ranges that permit them to encode their preferred stimuli with precision. Accordingly, the range of neural discharge (action potential frequency in hertz) of nociceptors is tuned to reflect forces (or heat) that potentially damage tissue.^{12,21,22} Therefore, nociceptors of the cornea are very sensitive and have a narrow response range while nociceptors of the skin have a very high threshold and broad response range.^{21,23,24} Typically, nociceptor activity begins well before tissue damage is imminent but reaches a peak as tissue failure forces (tissue destruction) are approached.²² This feature is important in understanding how injection volume can affect pain upon injection. The sensitivity of nociceptors to tissue distention is related to the fragility of the tissue injected. However, whether fragile tissues are stretched will be dependent upon the ability of the whole tissue to accept (disperse) large volumes of fluid without introducing tissue distortion into fragile tissue components. In this regard, it is important to remember that human tissue is generally a composite of both weak and tough components. This is one reason injection speed, injection volume, or site appears in some way to affect pain upon injection.

Nociceptor activation is ultimately dependent upon the ion channels present in the nociceptor endings (Figure 2). Mechanical nociception is dependent on the stretch-activated channels.^{25,26} When mechanical forces in tissue grow (tissue is stretched or compressed), stretch-activated channels open and neural discharge is initiated. In addition to direct actions of fluid volume (see above), intense mechanical forces may be mimicked in nociceptor mem-




Figure 2—Simplified representation of the peripheral ending of a nociceptor. The drawing illustrates mechanisms by which nociceptor endings may interact with parenterals. These include interaction of the injected solution with the ending via pH or osmotic pressure, release of mediators from intact cells (e.g., PGE₂), damaged cells (e.g., ATP), or from local vascular bed sources (5HT and BK). Weak passive currents evoked by these events may initiate action potentials at voltage activated Na⁺ and K⁺ channels. A minimum action potential frequency is required for perception. In the interest of simplicity, the nociceptor shown represents a composite of subtypes that include $A\delta$, C mechanothermal and chemically sensitive (polymodal) afferents. Specific receptors expressed for each ligand are shown by near association of the ligand. Some receptors form channels while other receptors are linked to channels by G proteins. Key: ATP, adenosine triphosphate; BK, bradykinin; Ca²⁺, calcium; CGRP, calcium gene related peptide; G, G protein; H⁺, proton; Na⁺, sodium; K⁺, potassium; PGE₂, prostaglandin E₂; SAC, stretch-activated channel; SP, substance P.

branes when hyposmotic fluids force water into cells. Expansion of neural membranes, due to water entry, will have profound influences on nociceptor activity, because membrane stretch mimics intense mechanical forces in tissue. Similarly, hyperosmotic influences that draw water from neural endings could activate compression sensitive channels with similar consequences. However, compression sensitive channels are still hypothetical.

Thermal nociceptors are a major subgroup of the nociceptive population. The mechanism of thermal nociception is not known but may be due to the release of intracellular stores of Ca^{2+} .²⁷ Agents that release Ca^{2+} from intracellular stores (calcium ionophores) may mimic the thermal transduction response of nociceptors. The capacity of parenterals to release intracellular Ca^{2+} has not received attention but could explain the injection site pain associated with some agents.

As noted above, nociceptors that have chemical as well as mechanical and thermal response capacities are called polymodal. Mechanical and thermal responses are primarily designed to protect tissue from external, superficial stimuli. In contrast, chemical responses of nociceptors are designed to detect the aftermath of tissue damage. Vascular cells, inflammatory cells, and blood-borne precursors are sources of proinflammatory agents (e.g., bradykinin, serotonin, prostaglandins) that are recognized by nociceptors.²⁸ In addition, damaged cells release ATP, a potent activator of nociceptors. Specific receptors, present in nociceptor endings, recognize and bind these agents (e.g. bradykinin receptors, serotonin receptors, prostaglandin receptors, and ATP receptors).²⁹ Nociceptors are diverse in their expression of these chemical receptors. The binding of chemical agents results in ion flow that excites nociceptors, causes immediate pain, and can induce local and distal events that contribute to long term "soreness" or hyperesthesia. In addition, other receptors detect general tissue events associated with injury, such as decreased pH.³⁰ Tissue acidity increases when vascular supply is lost or diminished due to trauma. The introduction of parenterals, whose pH mimics a damaged environment, will open proton sensitive channels and powerfully activate nociceptors. If parenterals bring about tissue damage, proinflammatory agents will both directly activate nociceptors and contribute to hyperesthesia in the injection field. Central nervous system mechanisms are also likely to contribute to long-term soreness at injection sites.³¹⁻³² Central nervous system (CNS) mechanisms of hyperesthesia are beyond the scope of this review. It is sufficient to recognize that these CNS mechanisms are dependent upon peripheral nociceptor activity for both initiation and maintenance.

Direct interaction of active drug, antimicrobials, or other additives with voltage activated ion channels is yet another means by which parenterals could influence the pain system. The nociceptive neuron is able to conduct signals (action potentials) because it has devised methods of separating ions (Na^+ , K^+ , Ca^{2+}) and controlling their flow across membranes through selective, voltage-activated ion channels.³³ In general, Na^+ flow favors signal generation and K^+ flow opposes signal generation. Nociceptors are activated, or their activity is modulated, by chemicals that interact with ion control mechanisms. The increase of ion flow in some channels (Na^+) or the decrease in ion flow in other channels (K^+) can cause or greatly enhance pain by modifying the range or rate of nociceptor discharge. Many naturally occurring and synthetic drugs interfere with ion control mechanisms at relatively low concentrations (micromolar to picomolar). The most well recognized of these are the plant and animal toxins. It is unclear to what extent drugs and/or formulation excipients in parenteral products could affect these ion control mechanisms.

Plants and animals have evolved chemical defenses or toxins [(e.g. capsaicin (plant toxin), melittin (bee toxin), dendrotoxin (snake toxin), charybdotoxin (a scorpion toxin)] that bind to ion channels or otherwise interact (or disrupt) nociceptor membranes.^{34,35} By holding channels open (e.g., Na^+ channels) or preventing channels from opening (e.g., K^+ channels), plant and animal toxins are able to induce

intense pain. Potentially, any foreign agent (e.g., antibiotic) introduced into tissue by injection could interact with ion channels by binding directly to the channel or blocking flow of ions through the channel pore. Agents could also interfere with the automatic "inactivation" process of ion channels (e.g., Na^+), thereby prolonging the duration of opening or preventing them from closing. Blocking of K^+ ion flow or increasing Na^+ ion flow could greatly enhance pain sensations either by directly activating nociceptors or increasing activity in those nociceptors which maintain a slow spontaneous discharge (see above).

Specific Mechanisms of Intramuscular and Subcutaneous Pain

Recent studies have investigated the specific mechanisms of intramuscular and subcutaneous pain. Graven-Nielson and co-workers have examined the factors associated with muscle pain in humans using hypotonic, isotonic, and hypertonic saline solutions by using microdialysis.³⁶⁻³⁷ It was reported that only a hypertonic saline solution resulted in increased intramuscular pressure and that pain activation in skeletal muscle is related to increased sodium and potassium content.³⁶ Furthermore, it appears that intramuscular pain is increased by temporal (repeated injections) and spatial summation (injections given at different sites).³⁷ For subcutaneous injections, pain appears to be reduced when a buffer at a nonphysiological pH is prepared at a lower buffer capacity, to enable a more rapid normalization to the pH at the injection site.³⁸ Jorgensen and co-workers have reported that pain following subcutaneous administration is related to the injection volume.³⁹

Compounds Reported to Cause Pain on Injection

A wide variety of drug classes have been reported to cause pain following parenteral administration. This list includes antibiotics, benzodiazepines, vitamins, iron, non-steroidal antiinflammatory agents, phenothiazines, local and general anesthetics, anticonvulsants, and peptide drugs. The drugs or formulations reported to cause pain, and potential strategies to reduce this event, are listed in Table 1.⁴⁰⁻¹²⁸ A review of this list indicates that pharmacological agents associated with pain on injection include a broad array of those used in clinical practice. Furthermore, the diversity in the structures does not seem to indicate specific chemical moieties or properties that can be linked to injection-associated pain. The reports of pain on injection seem to be the greatest with the penicillin, cephalosporin, and aminoglycoside antibiotics. In addition, the general anesthetics also seem to be associated with pain upon iv injection. It is unclear whether this would be primarily a function of their specific chemical structure, properties, and/or their formulations or secondary to the widespread use of these agents in hospitalized and ambulatory patients.

The formulator must be keenly aware of the difficulty in interpreting some of these experimental findings. It is critical for the formulator to discriminate the painful effect of the drug from that of the other excipients in the formulation. There is usually no problem when the drug is hydrophilic and can be readily formulated to achieve the desired pharmaceutical properties using an isotonic vehicle that is not associated with pain (e.g., normal saline). In contrast, for more lipophilic compounds that may require solubilization, complexation, or emulsification, it may be extremely difficult to determine the magnitude of pain associated with the injection of the drug molecule itself. It

Table 1—Drugs Reported To Cause Pain upon Injection^a

drug class and specific agents	nature of pain response	method of reducing adverse response	ref no.
Penicillin Antibiotics			
amoxicillin	1/3 patients pain upon injection	include lidocaine or procaine HCl	40
penicillin G	irritating after im injection, sciatic nerve damage, irritation and dysfunction possible	include procaine	41
penicillin G benzathine	pain after sc and im injection	none suggested	41
penicillin G procaine	pain after im injection	none suggested	41
sodium sulbactam and ampicillin	pain at im site	none suggested	42
Cephalosporin Antibiotics			
cefamandole	pain at im site	inject deeply into large muscle mass	43
cefoperazone	transient pain at im site	include lidocaine	43
cefotetan disodium	pain at injection site	include lidocaine	43
cefoxitin	pain at im site	none suggested	44
ceftazidime sodium	pain at im site	none suggested	43
ceftriaxone	pain upon injection	include lidocaine	45
ceftriaxone	pain at im site	none suggested	46
ceftriaxone	pain at im site	use lidocaine or buffered lidocaine	47
cefuroxime sodium	pain at im site	less painful when injected as a suspension rather than a solution, less pain when injected into the gluteus maximus or the vastus lateralis	43
Aminoglycoside Antibiotics			
amikacin sulfate	local irritation and pain after im and iv administration	none suggested	48
gentamicin sulfate	local irritation and pain after im and iv administration	none suggested	48
kanamycin sulfate	local irritation and pain after im and iv administration	none suggested	48
neomycin sulfate	local irritation and pain after im and iv administration	none suggested	48
streptomycin sulfate	local irritation and pain after im and iv administration	none suggested	48
timoxicillin	pain on im injection	none suggested	49
tobramycin sulfate	local irritation and pain after im and iv administration	none suggested	48
Antimalarials			
artemether	pain at im site	none suggested	50
Aminocyclitol Antibiotic			
spectinomycin	pain at im injection site	none suggested	51
trospectomycin	pain and tenderness at im injection site	none suggested	52
Tetracycline Antibiotics			
tetracycline	pain at im site	inject deeply into large muscle	53
Antiprotozoals and Anthelmintic			
pentamidine	pain on im injection site	iv infusion	54
oxamniquine	moderate to severe pain at im site for days to weeks	none suggested	55
Macrolide Antibiotics			
clarithromycin	pain on iv injection	formulate as an emulsion	56
Antineoplastics			
bleomycin	pain on intralesional injection	include lidocaine	57
methotrexate	pain at im site	subcutaneous injection	58
Benzodiazepines			
diazepam	pain on injection	formulate as an emulsion	59
diazepam	pain on injection	formulate as an emulsion	60
diazepam	pain and thrombophlebitis on injection	formulate as an emulsion	61
diazepam	pain and thrombophlebitis on injection	formulate as an emulsion	62
diazepam	pain on injection	formulate as mixed micelles	63
lorazepam	pain at im site	use sublingual administration	64
midazolam	pain during im injection	none suggested	65
Phenothiazines			
chlorpromazine	irritation after sc injection, pain after im injection	include procaine	66
promethazine HCl	irritation following sc injection	none suggested	67
Local Anesthetics			
bupivacaine	pain on sc injection	adjust pH to 7.0	68
lidocaine	pain on iv injection	increase pH	69
lidocaine	pain on sc injection	addition of sodium bicarbonate	70
lidocaine	pain on sc injection	warm solution	71
General Anesthetics			
etomidate	pain on iv injection	none suggested	72
etomidate	pain on iv injection	none suggested	73
etomidate	pain on injection	none suggested	74
methoxital	pain on injection	formulate as an emulsion	75
methohexitone	pain on iv injection	include lidocaine	76
propofol	pain on injection	include alfentanil	77
propofol	pain on iv injection	include lidocaine	78
propofol	pain on iv injection	include lidocaine or procaine	79
propofol	pain on iv injection	use antecubital fossa as injection site	80

Table 1—(Continued)

drug class and specific agents	nature of pain response	method of reducing adverse response	ref no.
General Anesthetics			
propofol	pain on injection	use forearm veins versus dorsal hand veins	81
propofol	pain on injection	include lidocaine	82
propofol	pain on injection	include alizapride instead of lidocaine	83
propofol	pain on injection	change temperature to 4 °C	84
propofol	pain on injection	formulate as an emulsion	85
propofol	pain on iv injection	reduce drug concentration	86
propofol	pain on iv injection	use lidocaine	87
propofol	pain on iv injection	use lidocaine	88
propofol	pain on injection	use lidocaine or aspiration of blood into syringe before injection	89
propofol	pain on iv injection	warm solution to 37 °C	90
propofol	pain on iv injection	lidocaine better in men; pethidine better in women	91
propofol	pain on iv injection	place smaller concentration in the aqueous phase	92
propofol	pain on iv injection	use lidocaine or alfentanil	93
propofol	pain on iv injection	lidocaine reduces incidence and severity; thiopentone only reduces severity	94
propofol	pain on iv injection	use alfentanil	95
propofol	pain on iv injection	use nitroglycerin ointment at the site	96
Skeletal Muscle Relaxants			
botulinum toxin A	pain at im injection site	none suggested	97
gallamine	pain on perineural injection	none suggested	98
methocarbamol	pain after iv injection, irritation at im site	none suggested	99
Antirheumatic			
myochrysin (gold sodium thiomalate)	pain at im site	include lidocaine	100
Adrenergic Agents			
epinephrine	intense pain on injection in patients with chronic nerve end neuromas	include lidocaine	101
phentolamine, prostaglandin E1, and papaverine	pain on injection	increase pH with sodium bicarbonate from 4.17 to 7.05	102
Peptides and Protein Drugs			
bradykinin	pain on intradermal injection	none suggested	103
erythropoietin	pain on sc injection	none suggested	104
erythropoietin	pain on sc injection	none suggested	105
erythropoietin	pain after sc injection	remove citrate buffer	106
erythropoietin	pain on sc injection	use lidocaine	107
erythropoietin	pain on sc injection	use lidocaine–procaine cream at the site	108
follicle stimulating hormone	pain on im and sc injection	none suggested	109
heparins	pain during sc injection	none suggested	110
insulin	pain on injection	optimize needle size and shape	111
Nonsteroidal Antiinflammatory Agents			
diclofenac	irritation on im injection	none suggested	112
diclofenac	pain at im injection	none suggested	113
ketorolac/trimethamine	pain at im injection site	decrease drug dose	114
Miscellaneous Agents			
diatrizoate meglumine	pain, burning, stinging after iv injection	none suggested	115
edetate calcium disodium	pain at im injection site	include procaine	116
haemophilus influenza type B vaccine	pain at im injection site	subcutaneous injection	117
immune serum globulin	pain at im injection site	iv infusion	118
iron dextran injection	pain after iv injection	none suggested	119
MNrgp120 HIV-1 vaccine	irritation after iv injection	use water-soluble prodrug	120
normal saline	pain at im site	use lidocaine–procaine cream at the site	121
phenytoin	pain at im site	prodrug formation	122
polymixin B sulfate	severe pain at im injection site	use intravenous injection	123
progesterone	pain after im injection	none suggested	124
testosterone	pain on im injection	use castor oil vehicle	125
theotepa	pain at im injection site	none suggested	126
trimethobenzamide	pain, stinging, burning after im injection	none suggested	127
Vitamins A, D, and K	severe local pain at im injection site	none suggested	128

^a im, intramuscular; sc, subcutaneous.

then becomes critical for the pharmaceutical scientist to characterize the extent to which a vehicle or other formulation excipients can cause pain on injection.

A review of the literature suggests that the intramuscular site is more often associated with pain upon injection compared to intravenous or subcutaneous administration. This most likely results from the prevalence of nerves in muscle tissue compared to subcutaneous tissue and the rapid dilution of the drug by blood when administered

intravenously, which may limit the concentration at the injection site.

Drug and Formulation Factors Associated with Pain on Injection

What factors should the experimentalist take into consideration when developing parenteral formulations with decreased pain on injection? A partial list is shown in

Table 2—Factors Associated with Pain on Injection

intrinsic properties of the drug
drug structure
drug concentration in formula
nature and type of excipients used in formulation
buffers
cosolvents
chelating agents
antimicrobial preservatives
properties of the final formulation
pH
tonicity
osmolarity
solution temperature
drug concentration
injection volume
injection procedure
individual performing the procedure must be trained and consistent from time to time
needle size and shape
site and location within injection site
speed and rate of injection

Table 2. This list is by no means inclusive, as many investigators have personal knowledge of formulation factors or strategies that have been associated with a reduction of pain following injection. The fundamental question to be asked is whether the drug and its intrinsic properties are associated with pain on injection. Whether a drug causes pain could be predicted on the basis of potential interactions with nociceptors (see the section on mediation of pain). For example, antibiotics such as cephalosporins have been reported to cause pain on injection.¹²⁹ Since these formulations are administered in solvent vehicles that have been shown not to cause pain, it can be proposed that the drug itself is the responsible agent. In such cases, it may be possible to reduce the extent of pain by decreasing the drug concentration that the tissue is exposed to following the injection.

Whether the individual formulation components cause pain themselves should be critically evaluated during the development of new products. Buffers, cosolvents, antimicrobial preservatives, and chelating agents may, in some cases, be associated with injection site pain.^{106,130,131} Final formulation factors such as pH, osmolarity, tonicity, solution temperature, drug concentration, and injection volume may be associated with pain upon injection. For peptides, it has been suggested that aggregation of proteins and particulates in general may contribute to pain. However, there has been no systematic investigation of the impact of particle size on pain.

Various factors associated with the injection procedure should be standardized in studies. It is important to ensure that the investigator minimizes the pain associated with the injection procedure itself and is consistent in this procedure each time. The needle size and shape, the depth, the specific injection site, and the speed and rate of injection need to be well-defined since they can affect the extent of pain.^{37,38} For example, an adequate needle length and diameter should be used to ensure that an injection site is actually in the muscle tissue versus subcutaneous tissue or vice versa for the particular site in the animal or patient. Suggestions for the appropriate needle length and gauge for various injections can be found in standard pharmaceutical textbooks.¹ With respect to temperature, the data is unclear and therefore it is difficult to determine whether ice can reduce pain associated with intramuscular injections. In contrast, distraction or support of the individual can be used in pediatric patients.¹³²

Methods to Reduce or Eliminate pain On injection

What approaches might a formulator use to reduce or eliminate pain associated with injection? Table 1 indicates some approaches that have been investigated in the past. The question that must be addressed when making modifications in the formulation is whether this will impact on drug release and or availability. Simple approaches that would not require reformulation include (1) switching from intramuscular to intravenous administration or from intramuscular to subcutaneous administration, (2) changing the site or depth of injection, (3) reducing drug concentration at the site of injection and (4) optimizing the needle size and shape.^{43,53,54,58,80,81,86,111,114,117,118,123}

If the drug itself is found to be responsible for the pain on injection or tissue damage, the formulator could use a prodrug or salt form;^{70,102,120} formulate the drug as a suspension or emulsion rather than as a solution;^{43,56,59–62,75,85,125} encapsulate the drug in some type of biocompatible/biodegradable carrier such as liposomes,¹³³ microspheres,¹³⁴ or mixed micelles;⁶³ or develop other novel drug complexes. Formulation changes can also involve modifications in the type of buffer, cosolvents, or other excipients used in the product^{70,102,106,125} or altering the final pH of the product.^{68–70,102} If necessary, the drug product labeling may include a recommendation that a specific vehicle or local anesthetic or other protective agent be administered concurrently with the drug.^{40,41,43,45,47,57,66,76–79,82,83,87–89,91,93–95,100,101,107,108,116,121} The addition of compounds such as procaine or lidocaine to an injection will block the transmission and perception of pain (see mediation of pain) associated with injection via their action on sodium receptors. However, the question that needs to be addressed is whether this is a desirable to utilize this multiple drug approach for long-term therapy. If an injectable is causing pain, which may be associated with damage at the injection site, and knowing that pain is the way of warning our body of an undesirable effect, is it correct to block this effect with injectables, particularly those which might be prescribed long-term? What would be the consequences on the function and/or structure of repeated injections at a site or series of sites in subcutaneous or muscle tissue? The formulator must have an understanding of the toxic effects of an injectable at the site.

Experimental Systems and Designs to Study Pain on Injection

While numerous experimental systems have been proposed to study the extent of tissue damage, particularly in the venous tissue or skeletal muscle, there are few methods useful for evaluating the extent of pain on injection. Comerski and co-workers have compared the various animal methods for assessing pain and muscle irritation associated with parenteral products.⁵ While animal studies are important in the design of these products and have generally provided a fairly good rank order with human studies, the ultimate test of a new formulation will occur with clinical studies. As stated earlier, clinical investigators should be aware and incorporate this aspect into their clinical design.

For intravenous formulations, the toxicity of these products can be studied by investigating red blood cell hemolysis⁹ or the venous irritation in the rabbit ear vein.¹⁰ Irritation to skeletal muscle can be determined using the rabbit intramuscular injection model,¹³⁵ the rat in vivo intramuscular injection model,^{6–8,133} the rodent in vitro

muscle model,^{2,3} and the L6 myoblast cell line.¹³⁶ A specific method to investigate the toxicity of formulations on subcutaneous tissue has not been reported to date.

Examples of methods that can be utilized to determine the extent of pain on injection using an animal model include the rat paw lick model^{4,137} and the conscious rat iv model.¹³⁸ Even though the rat paw lick model can evaluate the adverse effects of an injectable on the tissue and the pain on injection, this system is extremely labor intensive and requires the investigator to be consistent in their reporting of the animal activities. Furthermore, it may be difficult to discriminate between formulations due to the variability associated with these models. In contrast, the conscious rat intravenous model requires the presence of instrumentation to record activity of the animals following injection. The reader is referred to the specific papers for more details on these methods.

The experimental design can also impact on the determination of formulation-induced pain. Use of appropriate controls, methods used to calibrate or normalize the systems with respect to individuals or time, are critical requirements to achieve useful experimental results. In animal studies, the investigator(s) should attempt to familiarize the animals with the experimental systems and themselves prior to the study day and should be consistent in scheduling their experiments with respect to the day of the week and time of day. The advantage of controlling these latter factors lies in the potential reduction of stress responses in animals that could cause variability in the experimental findings.

Clinical studies should be blinded, randomized, and comprised of crossover designs with appropriate time intervals between the phases. The difficulty in clinical trials, which would specifically investigate the pain associated with an injection, arises from subjectivity associated with pain reporting. This difficulty is confounded by the inability to incorporate adequate positive and negative controls to gauge and/or normalize the relative magnitude of pain associated with the administration of the various injectable products. Due to the reluctance of the general population to injections, it would not be unexpected for IRB (Internal Review Board) or patients to be less than enthusiastic to approve or participate in such studies that include controls to provide a standard by which one can compare different formulations.

Furthermore, the investigator can introduce bias in the clinical reports in how the questions are prepared or asked to the subject. Investigators should avoid general questions such as "How did the injection feel?" This general type of question may not provide sufficient discrimination between formulations unless the pain is obvious and severe. In designing and conducting studies where an injection may be associated with pain, a clinical psychologist or other health care professional trained in pain assessment should be included in the process. This individual can provide the formulator and/or clinician with suitable approaches to quantify injection site pain in patients.

Conclusions

While injectable formulations continue to be an important mainstay in development of new products, the potential of these parenteral products to cause pain on injection, which may or may not be associated with tissue damage, needs to be recognized. The formulation scientist needs to be aware during the development of new products of potential formulation factors and considerations that may be associated with pain on injection. Furthermore, the

investigation of whether a formulation causes pain and/or damage on injection needs to be addressed during the process of optimizing parenteral formulations for solubility and/or stability considerations. For specifics on the solubility principles and practices in parenteral drug dosage form development, the readers are referred to the work of Sweetana and Akers.¹³⁹ It also becomes critical for clinical scientists to investigate the reports of pain on damage. While it may not be entirely possible to reduce pain and/or damage on injection for every parenteral formulation, the goal should be to minimize this aspect to enhance the therapeutic success of the given product.

References and Notes

1. Turco, S. J. *Sterile Dosage Forms: Their Preparation and Clinical Application*, 4th ed.; Lea & Febiger, Philadelphia, 1994; pp 2–10.
2. Brazeau, G. A.; Fung, H.-L. Use of an In Vitro Model for the Assessment of Muscle Damage from Intramuscular Injections: In Vitro–in Vivo Correlation and Predictability with Mixed Solvent Systems. *Pharm. Res.* **1989**, *6*, 766–771.
3. Brazeau, G. A.; Fung, H.-L. An In Vitro Model to Evaluate Muscle Damage Following Intramuscular Injections. *Pharm. Res.* **1989**, *6*, 167–170.
4. Gupta, P. K.; Patel, J. P.; Hahn, K. R. Evaluation of Pain and Irritation Following Local Administration of Parenteral Formulations Using the Rat Paw Lick Model. *J. Parent. Sci. Technol.* **1994**, *48*, 159–166.
5. Comerreski, C. R.; Williams, P. D.; Bregman, C. L.; Hottendorf, G. H. Pain on Injection and Muscle Irritation: A Comparison of Animal Models for Assessing Parenteral Products. *Fundam. Appl. Toxicol.* **1986**, *6*, 335–338.
6. Evans, L. A.; Genereux, P. E.; Gibbs, E. M.; Sutton, S. C. Predicting Injection Site Muscle Damage. III: Evaluation of Intramuscular Formulations in the L6 cell Model. *Pharm. Res.* **1996**, *13*, 1585–1587.
7. Sutton, S. C.; Evans, L. A.; Rinaldi, M. T.; Norton, K. A. Predicting Injection Site Muscle Damage. II: Evaluation of Extended Release Parenteral Formulations in Animal Models. *Pharm. Res.* **1996**, *13*, 1514–1518.
8. Sutton, S. C.; Evans, L. A.; Rinaldi, M. T.; Norton, K. A. Predicting Injection Site Muscle Damage. I: Evaluation of Immediate Release Parenteral Formulations in Animal Models. *Pharm. Res.* **1996**, *13*, 1507–1513.
9. Reed, K. W.; Yalkowsky, S. H. Lysis of Human Red Blood Cells in the Presence of Various Cosolvents. *J. Parenter. Sci. Technol.* **1985**, *39*, 64–69.
10. Krzyzaniak, J. F.; Raymond, D. M.; Yalkowsky, S. H. Lysis of Human Red Blood Cells I: Effect of Contact Time on Water Induced Hemolysis. *PDA J. Pharm. Sci. Technol.* **1996**, *50*, 223–226.
11. Ward, G. H.; Yalkowsky, S. H. Studies in Phlebitis. V: Hemolysis as a Model for Phlebitis. *J. Parenter. Sci. Technol.* **1993**, *47*, 44–46.
12. Meyer, R. A.; Campbell, J. N.; Raja, S. N. Peripheral neural mechanisms of cutaneous hyperalgesia. In *Advances in Pain Research and Therapy*; Fields, H. L., Dubner, R., Cervero, F. Eds.; Raven Press: New York, 1985; pp 53–71.
13. Campbell, J. N.; Raja, S. N.; Cohen, R. H.; Manning, D. C.; Kahn, A. A.; Meyer, R. A. Peripheral neural mechanisms of nociception. In *Textbook of Pain*; Wall, P. D., Melzack, R., Eds.; Churchill Livingstone Inc.: New York, 1989; pp 22–45.
14. Mense, S. Nociception from skeletal muscle in relation to clinical muscle pain. *Pain* **1993**, *54*, 241–289.
15. Schaible, H.-G.; Grubb, B. D. Afferent and spinal mechanisms of joint pain. *Pain* **1993**, *55*, 5–54.
16. Cervero, F. Mechanisms of visceral pain: Past and present. In *Visceral Pain*; Gebhart, G. F., Ed.; IASP Press: Seattle, 1985; pp 25–40.
17. Bessou, P.; Perl, E. R. Response of cutaneous sensory units with unmyelinated fibers to noxious stimuli. *J. Neurophysiol.* **1969**, *32*, 1025–1042.
18. Adriaensen, H.; Gybels, J.; Handwerker, H. O.; Van Hees, J. Response properties of thin myelinated (A- δ) fibers in human skin nerves. *J. Neurophysiol.* **1983**, *49*, 111–122.
19. Torebjörk, H. E.; Schady, W.; Ochoa, J. L. Sensory correlates of somatic afferent fibre activation. *Hum. Neurobiol.* **1984**, *3*, 15–20.

20. Simone, D. A.; Marchettini, P.; Caputi, G.; Ochoa, J. L. Identification of muscle afferents subserving sensation of deep pain in humans. *J. Neurophysiol.* **1994**, *72*, 883–889.
21. Garell, P. C.; McGillis, S. L. B.; Greenspan, J. D. Mechanical response properties of nociceptors innervating feline hairy skin. *J. Neurophysiol.* **1996**, *75*, 1177–1189.
22. Loughner, B. A.; Miller, J.; Broumand, V.; Cooper, B. Y. The development of strains, forces, and nociceptor activity in retrodiscal tissues of the temporomandibular joint of male and female goats. *Exp. Brain Res.* **1997**, *113*, 311–326.
23. Belmonte, C.; Giraldez, F. Responses of cat corneal sensory receptors to mechanical and thermal stimulation. *J. Physiol. (London)* **1981**, *321*, 355–368.
24. MacIver, M. B.; Tanelian, D. L. Structural and functional specialization of A δ and C fiber free nerve endings innervating rabbit corneal epithelium. *J. Neurosci.* **1993**, *13*, 4511–4524.
25. Morris, C. E. Mechanosensitive ion channels. *J. Membr. Biol.* **1990**, *113*, 93–107.
26. Sackin, H. Mechanosensitive channels. *Annu. Rev. Physiol.* **1995**, *57*, 333–353.
27. Reichling, D. B.; Levine, J. D. Heat transduction in rat sensory neurons by calcium-dependent activation of a cation channel. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 7006–7011.
28. Cooper, B. Y.; Sessle, B. J. Anatomy, physiology, and pathophysiology of the trigeminal system and its relationship to the development and maintenance of paresthesias, dysesthesias, and chronic pain. In *Clinics of North America*; Grigg, J., LaBanc, J., Eds.; W. B. Saunders: New York, 1992.
29. Rang, H. P.; Bevan, S. J.; Dray, A. Chemical activation of nociceptive peripheral neurones. *Br. Med. Bull.* **1991**, *47*, 534–548.
30. Bevan, S.; Geppetti, P. Protons: Small stimulants of capsaicin-sensitive sensory nerves. *Trends Neurosci.* **1994**, *17*, 509–512.
31. Sluka, K. A.; Dougherty, P. M.; Sorkin, L. S.; Willis, W. D.; Westlund, K. N. Neural changes in acute arthritis in monkeys. III. Changes in substance P, calcitonin gene-related peptide and glutamate in the dorsal horn of the spinal cord. *Brain Res. Rev.* **1992**, *17*, 29–38.
32. Meller, S. T.; Gebhart, G. F. Nitric oxide (NO) and nociceptive processing in the spinal cord. *Pain* **1993**, *52*, 127–136.
33. Hille, B. *Ionic Channels of Excitable Membranes*; Sinauer Associates Inc.: Sunderland, 1992.
34. Dreyer, F. Peptide toxins and potassium channels. *Rev. Physiol. Biochem. Pharmacol.* **1990**, *115*, 93–136.
35. Cooper, B. Y.; Bomalaski, J. S. Activation of nociceptors by melittin and PLAP peptide. *Exp. Brain Res.* **1994**, *100*, 18–28.
36. Graven-Nielsen, T.; McArdle, A.; Phoenix, J.; Arendt-Nielsen, L.; Jensen, T. S.; Jackson, M. J.; Edwards, R. H. In Vivo Model of Muscle Pain: Quantification of Intramuscular Chemical, Electrical, and Pressure Changes Associated with Saline-induced Muscle Pain in Humans. *Pain* **1997**, *69*, 137–143.
37. Graven-Nielsen, T.; Arendt-Nielsen, L.; Svensson, P.; Jensen, T. S. Quantification of Local and Referred Muscle Pain in Humans After Sequential I. M. Injections of Hypertonic Saline. *Pain* **1997**, *69*, 111–117.
38. Fransson, J.; Espander-Jansson, A. Local Tolerance of Subcutaneous Injections. *J. Pharm. Pharmacol.* **1996**, *48*, 1012–1015.
39. Jorgensen, J. T.; Romsing, J.; Rasmussen, M.; Moller-Sonnergaard, J.; Vang, L.; Musaeus, L. Pain Assessment of Subcutaneous Injections. *Ann. Pharmacother.* **1996**, *30*, 729–732.
40. Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Amoxicillin Injectable: A review of its Antibacterial Spectrum, Pharmacokinetics and Therapeutic Use. *Drugs* **1979**, *18*, 169–184.
41. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 230–368.
42. Odugbemi, T. Open Evaluative Study of Sulbactam/Ampicillin with or without Probenecid in Gonococcal Infections in Lagos. *Curr. Therap. Res.* **1987**, *41*, 542–551.
43. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 106–186.
44. Rosaschino, F.; Vita, C. R. G.; Bosco, U.; Castelli, F.; Vercelloni, M. Clinical Study with Cefoxitin in Pediatrics. *Drugs Exp. Clin. Res.* **1985**, *11*, 195–199.
45. Schichor, A.; Berstein, B.; Weinerman, H.; Fitzgerald, J.; Yordan, E.; Schechter, N. Lidocaine as a Diluent for Ceftriaxone in the Treatment of Gonorrhoea. Does it Reduce the Pain on the Injection? *Arch. Pediatr. Adolesc. Med.* **1994**, *148*, 72–75.
46. Barnett, E. D.; Teele, D. W.; Klein, J. O.; Cabral, H. J.; Kharasch, S. J. comparison of Ceftriaxone and Trimethoprim-sulfamethoxazole for Acute Otitis Media. *Pediatrics* **1997**, *99*, 23–28.
47. Hayward, C. J.; Nafziger, A. N.; Kohlhepp, S. J.; Bertino, J. S., Jr. *Antimicrob. Agents Chemother* **1996**, *40*, 485–487.
48. McEvoy, G. K. *AHFS 97 Drug Information*; Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 56–74.
49. Tachikawa, S.; Tachibana, A. J. Pain Response of Rabbits to the Intramuscular Injection of Antibiotics, With Special Reference to Timoxillin, a New Penicillin Derivative. *Toxicol. Sci.* **1977**, *2*, 273–280.
50. Karbwang, J.; Tin, T.; Rimchala, W.; Sukontason, K.; Namsiripongpun, V.; Thanavibul, A.; Bangchang, K.; Laothavorn, P.; Bunnag, D.; Harinasuta, T. Comparison of Artemether and Quinine in the Treatment of Severe Falciparum Malaria in South-east Thailand. *Trans. R. Soc. Trop. Med. Hyg.* **1995**, *89*, 668–671.
51. Panikabuta, K.; Lee, C. T.; Ho, B.; Bamberg, P. Single Dose Oral Norfloxacin of Intramuscular Spectinomycin to Treat Gonorrhoea: Analysis of Efficacy and Patient Preference. *Genitourin. Med.* **1988**, *64*, 235–240.
52. Novak, E.; Paxton, L. M.; Bye, A.; Patel, R.; Zurenko, G. E.; Francom, S. F. Human Safety and Pharmacokinetics of a Single Intramuscular Dose of a Novel Spectinomycin Analogue, Trospetomycin (U-63336F). *Antimicrob. Agents Chemother.* **1990**, *34*, 2342–2347.
53. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 369–386.
54. Sands, M.; Kron, M. A.; Brown, R. B. Pentamidine: A Review. *Rev. Infect. Dis.* **1985**, *7*, 625–634.
55. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997.
56. Lovell, M. W.; Johnson, H. W.; Hui, H.-W.; Cannon, J. B.; Gupta, P. K.; Hsu, C. C. Less-painful Emulsion Formulations for Intravenous Administration of Claritromycin. *Int. J. Pharm.* **1994**, *109*, 45–57.
57. Manz, L. A.; Pelachyk, J. M. Bleomycin Lidocaine Mixture Reduces Pain on Intralesional Injection in the Treatment of Recalcitrant Verrucae. *J. Am. Acad. Dermatol.* **1991**, *25*, 524–526.
58. Brooks, P. J.; Spruill, W. J.; Parish, R. C.; Birchmore, D. A. Pharmacokinetics of Methotrexate Administered by Intramuscular and Subcutaneous Injections in Patients with Rheumatoid Arthritis. *Arthritis Rheum.* **1990**, *33*, 91–94.
59. Bullimore, D. W. A Comparison of the Incidence of Injection Pain with Two Different Diazepam Formulations—Valium and Diazemuls. *Clin. Ther.* **1982**, *4*, 367–368.
60. Craig, M.; Fielding, J. F. Drug Efficacy and Side-effects Following Different Formulations of Intravenous Diazepam. *Ir. J. Med. Sci.* **1982**, *151*, 79–80.
61. Selander, D.; Curelaru, I.; Steffansson, T. Local Discomfort and Thrombophlebitis Following Intravenous Injection of Diazepam. A Comparison between a Glycerofol-water Solution and a Lipid Emulsion. *Acta Anaesthesiol. Scand.* **1981**, *25*, 516–518.
62. Von Dardel, O.; Mebius, C.; Mossberg, T.; Svensson, B. Fat Emulsion as a Vehicle for Diazepam. A Study of 9492 Patients. *Br. J. Anaesthes.* **1983**, *55*, 41–47.
63. Galletly, D. C.; Wilson, L. F.; Treuren, B. C.; Boon, B. P. Diazepam Mixed Micelles—Comparison with Diazepam in Propylene Glycol and Midazolam. *Anaesth. Intens. Care* **1985**, *13*, 352–354.
64. Gram-Hansen, P.; Schultz, A. Plasma Concentrations Following Oral and Sublingual Administration of Lorazepam. *Int. J. Clin. Pharmacol. Ther. Toxicol.* **1988**, *26*, 323–324.
65. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1779–1824.
66. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1719–1763.
67. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 27–30.
68. Cheney, P. R.; Molzen, G.; Tandberg, D. The Effect of Ph Buffering on Reducing the Pain Associated with Subcutaneous Infiltration of Bupivacaine. *Am. J. Emerg. Med.* **1991**, *9*, 147–148.
69. Steinbrook, R. A.; Hughes, N.; Fanciullo, G.; Manzi, D.; Ferrante, F. M. Effects of Alkalinization of Lidocaine on the Pain of Skin Infiltration and Intravenous Catheterization. *J. Clin. Anesth.* **1993**, *5*, 456–458.
70. Parham, S. M.; Pasiaka, J. L. Effect of pH Modification by Bicarbonate on Pain after Subcutaneous Lidocaine Injection. *Can. J. Surg.* **1996**, *39*, 31–35.

71. Mader, T. J.; Playe, S. J.; Garb, J. L. Reducing the Pain of Local Anesthetic Infiltration: Warming and Buffering Have a Synergistic Effect. *Ann. Emerg. Med.* **1994**, *23*, 550–554.
72. Yelavich, P. M.; Holmes, C. M. Etomidate: A Foreshortened Clinical Trial. *Anaesthes. Intens. Care.* **1980**, *8*, 479–483.
73. Doenicke, A.; Kugler, A.; Vollmann, N.; Suttman, H.; Taeger, K. Etomidate Using a New Solubilizer. Experimental Clinical Studies on Venous Tolerance and Bioavailability. *Anaesthesist* **1990**, *39*, 75–80.
74. Ganta, R.; Verma, R. Pain on Injection and Venous Sequelae Following Two Formulations of Etomidate. *Eur. J. Anaesthesiol.* **1989**, *6*, 431–434.
75. Westrin, P. Methohexital Dissolved in Lipid Emulsion for Intravenous Induction of Anesthesia in Infants and Children. *Anesthesiology* **1992**, *76*, 917–921.
76. Simpson, K. H.; Halsall, P. J.; Sides, C. A.; Keeler, J. F. Pain on Injection of Methohexitone. The Use of Lignocaine to Modify Pain on Injection of Methohexitone during Anaesthesia for Electroconvulsive Therapy *Anaesthesia* **1989**, *44*, 688–689.
77. Dru, M.; Lory, C.; Journois, D.; Playe, E. The Effect of Alfentanil on Pain Caused by the Injection of Propofol During Anesthesia Induction in Children. *Can. Anesthesiol.* **1991**, *39*, 383–386.
78. King, S. Y.; Davis, F. M.; Wells, J. E.; Murchinson, D. J.; Pryor, P. J. Lidocaine for the Prevention of Pain Due to Injection of Propofol. *Anesth. Analg.* **1992**, *74*, 246–249.
79. Nicol, M. E.; Moriarty, J.; Edwards, J.; Robbie, D. S.; A'Hern, R. P. Modification of Pain on Injection of Propofol—A Comparison between Lignocaine and Procaine. *Anaesthesia* **1991**, *46*, 67–69.
80. Scott, R. P.; Saunders, D. A.; Norman, J. Propofol: Clinical Strategies of Preventing the Pain on Injection. *Anaesthesia* **1988**, *43*, 92–94.
81. McCullough M. J.; Lees, N. W. Assessment and Modification of Pain on Induction with Propofol (Diprivan). *Anaesthesia* **1985**, *40*, 1117–1120.
82. Gehan, G.; Karoubi, P.; Quinet, F.; Leroy, A.; Rathat, C.; Pourriat, J. L. Optimal Dose of Lignocaine for Preventing Pain on Injection of Propofol. *Br. J. Anaesthes.* **1991**, *66*, 324–326.
83. Zaouk, G.; Gilbert, E.; Dubois, A.; Jacobs, D.; Balatoni, E. Alizaprodol Does Reduce Pain on Injection of Propofol—Comparison with Lidocaine. *Br. J. Anaesth.* **1993**, *70*, P6.
84. McCrirrick, A.; Hunter, S. Pain on Injection of Propofol: The Effect of Injectate Temperature. *Anaesthesia* **1990**, *45*, 443–444.
85. Hynynen, M.; Korttila, K.; Tammisto, T. Pain on I. V. Injection of Propofol (ICI 35 868) in Emulsion Formulation. *Acta Anaesthesiol. Scand.* **1985**, *29*, 651–652.
86. Klement, W.; Arndt, J. O. Pain on Injection of Propofol: Effects of Concentration and Diluent. *Br. J. Anaesth.* **1991**, *67*, 281–284.
87. Alyafi, W. A.; Rangasami, J. Reduction of Propofol Pain – Fentanyl vs Lidocaine. *Middle East J. Anesthesiol.* **1996**, *13*, 613–619.
88. Gajraj, N. M.; Nathanson, M. H. Preventing Pain During Injection of Propofol: The Optimal dose of Lidocaine. *J. Clin. Anesth.* **1996**, *8*, 575–577.
89. McDonald, D. S.; Jameson, P. Injection Pain with Propofol. Reduction with Aspiration of Blood. *Anaesthesia* **1996**, *51*, 878–880.
90. Fletcher, G. C.; Gillespie, J. A.; Davidson, J. A. The Effect of Temperature Upon Pain During Injection of Propofol. *Anaesthesia* **1996**, *51*, 498–499.
91. Lyons, B.; Lohan, D.; Flynn, C.; McCarroll, M. Modification of Pain on Injection of Propofol. A Comparison of Pethidine and Lignocaine. *Anaesthesia* **1996**, *51*, 394–395.
92. Doenicke, A. W.; Roizen, M. F.; Rau, J.; Kellerman, W.; Bahl, J. Reducing Pain During Propofol Injection: The role of the Solvent. *Anesth. Analg.* **1996**, *82*, 472–474.
93. Nathanson, M. H.; Gajraj, N. M.; Russell, J. A. Prevention of Pain on Injection of Propofol: A Comparison of Lidocaine with Alfentanil. *Anesth. Analg.* **1996**, *82*, 469–471.
94. Haugen, R. D.; Vaghadia, H.; Waters, T.; Merrick, P. M. Thiopentone Pretreatment for Propofol Injection Pain in Ambulatory Patients. *Can. J. Anaesth.* **1995**, *42*, 1108–1112.
95. Fletcher, J. E.; Seavell, C. R.; Bowen, D. J. Pretreatment with Alfentanil Reduces Pain Caused by Propofol. *Br. J. Anaesth.* **1994**, *72*, 342–344.
96. Wilkinson, D.; Anderson, M.; Gauntlett, I. S. Pain on Injection of Propofol: Modification by Nitroglycerin. *Anesth. Analg.* **1993**, *77*, 1139–1142.
97. Lorentz, I. T.; Subramaniam, S. S.; Yiannikas, C. Treatment of Idiopathic Spasmodic Torticollis with Botulinum Toxin A: A Double-blind Study on 23 Patients. *Moving Disorder* **1991**, *6*, 145–150.
98. Chabal, C.; Jacobson, L.; Russell, L. C.; Burchiel, K. J. Pain Responses to Perineural Injection of Normal Saline, Gallamine, and Lidocaine in Humans. *Pain* **1989**, *36*, 321–325.
99. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1011–1023.
100. Movalesky, A.; Sherry, D. D.; Lehman, T. J. The Use of Lidocaine to Reduce the Pain of Myochrysin Injections for Children with Juvenile Rheumatoid Arthritis. *J. Rheumatol.* **1986**, *13*, 356–357.
101. Chabal, C.; Jacobson, L.; Russell, L. C.; Burchiel, K. J. Pain Response to Perineural Injection of Normal Saline, Ephedrine, and Lidocaine in Humans. *Pain* **1992**, *49*, 9–12.
102. Moriel, E. Z.; Rajfer, J. Sodium Bicarbonate Alleviated Penile Pain Induced by Intracavernous Injections for Erectile Dysfunction. *J. Urol.* **1993**, *149*, 1299–1300.
103. Manning, D. C.; Raja, S. N.; Meyer, R. A.; Campbell, J. N. Pain and Hyperalgesia after Intradermal Injection of Bradykinin in Humans. *Clin. Pharmacol. Ther.* **1991**, *50*, 721–729.
104. Frenken, L. A.; van Lier, H. J.; Gerlag, P. G.; den Hartog, M.; Koene, R. A. Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis. *Br. Med. J.* **1991**, *303*, 288.
105. Lui, S. F.; Leung, C. B.; Li, P. K. T.; Lai, K. N. Pain After Subcutaneous Injection of Erythropoietin. *Br. Med. J.* **1991**, *303*, 6806.
106. Frenken, L. A.; van Lier, H. J.; Jordans, J. G.; Leunissen, K. M.; van Leusen, R.; Verstappen, V. M.; Koene, R. A. Identification of the Component Part in an Epoetin Alfa Preparation that Causes Pain after Subcutaneous Injection. *Am. J. Kidney Dis.* **1993**, *22*, 553–556.
107. Alon, U. S.; Allen, S.; Rameriz, Z.; Warady, B. A.; Kaplan, R. A.; Harris, D. J. Lidocaine for the Alleviation of Pain Associated with Subcutaneous Erythropoietin Injection. *J. Am. Soc. Nephrol.* **1994**, *5*, 1161–1162.
108. Morris, K. P.; Hughes, C.; Hardy, S. P.; Matthes, J. N.; Coulthard, M. G. Pain after Subcutaneous Injection of Recombinant Human Erythropoietin: Does Emla Cream Help? *Nephrol. Dial. Transplant.* **1994**, *9*, 1299–1301.
109. Out, H. J.; Reimitz, P. E.; Bennink, H. J. A Prospective, Randomized Study to Assess the Tolerance and Efficacy of Intramuscular and Subcutaneous Administration of Recombinant Follicle-stimulating Hormone (Puregon). *Fertil. Steril.* **1997**, *67*, 278–283.
110. Billon, N.; Gloaguen, F.; Funck-Brentano, C.; Jaillon, P. Clinical Evaluation of Pain During Subcutaneous Injections of Low Molecular Weight Heparins in Healthy Volunteers. *Br. J. Clin. Pharmacol.* **1994**, *37*, 395–397.
111. Chantelau, E.; Lee, D. M.; Hemmann, D. M.; Zipfel, U.; Echterhoff, S. What Makes Insulin Injections Painful? *Br. Med. J.* **1991**, *303*, 26.
112. Vaccarino, V.; Sirtori, C. R.; Bufalino, L. Local and Systematic Tolerability of Piroxicam after Intramuscular Administration in Healthy Volunteers. *Curr. Ther. Res. Clin. Exp.* **1989**, *45*, 1–13.
113. Pillans, P. I.; O'Connor, N. Tissue Necrosis and Necrotizing Fasciitis after Intramuscular Administration of Diclofenac. *Ann. Pharmacother.* **1995**, *29*, 264–266.
114. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1457–1558.
115. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1919–1962.
116. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 2329–2342.
117. Lueng, A. K.; Chiu, A. S.; Siu, T. O. Subcutaneous Versus Intramuscular Administration of Haemophilus Influenza Type B Vaccine. *J. R. Soc. Health.* **1989**, *109*, 71–73.
118. Schwartz, R. S. Overview of the Biochemistry and Safety of a New Native Intravenous Gamma Globulin, IGIV, pH 4.25. *Am. J. Med.* **1987**, *83*, 46–51.
119. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 1070–1076.
120. Eron, J. J.; Ashby, M. A.; Giordano, M. F.; Chernow, M.; Reiter, W. M.; Deeks, S. C.; Lavelle, J. P.; Conant, M. A.; Yang, B. G.; Pate, P. G.; Torres, R. A.; Mitsuyasu, R. T.; Twaddell, T. Randomized Trial of MNrpg120 HIV-1 Vaccine in Symptomless HIV-1 Infection. *Lancet* **1996**, *348*, 1547–1541.
121. Himelstein, B. P.; Cnaan, A.; Blackall, C. S.; Zhao, H.; Cavalieri, G.; Cohen, D. E.; Topical Application of Lidocaine—

- Prilocaine (EMLA) Cream Reduces the Pain of Intramuscular Infiltration of Saline Solution. *J. Pediatr.* **1996**, *129*, 718–721.
122. Jamerson, B. D.; Dukes, G. E.; Brouwer, K. L.; Donn, K. H.; Messenheimer, J. A.; Powell, J. R. Venous Irritation Related to Intravenous Administration of Phenytoin Versus Fosphenytoin. *Pharmacotherapy* **1994**, *14*, 47–52.
 123. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 386–408.
 124. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 2466–2476.
 125. Mackey, M. A.; Conway, A. J.; Handelsman, D. J. Tolerability of Intramuscular Injections of Testosterone Ester in Oil Vehicle. *Hum. Reprod.* **1995**, *10*, 862–865.
 126. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 673–893.
 127. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 2252–2263.
 128. McCormick, P. A.; Hughes, J. E.; Burroughs, A. K.; McIntyre, N. Reformulation of Injectable Vitamin A: Potential Problems. *Br. Med. J.* **1990**, *301*, 924.
 129. Arnold, J.; Berger, A.; March, L. A Comparative Evaluation of Pain Following Intramuscular Administration of Three Parenteral Antimicrobials to Health Volunteers. *Curr. Ther. Res.* **1988**, *43*, 1082–1088.
 130. Doenicke, A.; Nebauser, A. E.; Hoernecke, R.; Mayer, M.; Roizen, M. F. Osmolarities of Propylene Glycol Containing Drug Formulations for Parenteral Use. Should Propylene Glycol be Used as a Solvent. *Anaesthes. Crit. Care*, **1992**, *75*, 431–435.
 131. McEvoy, G. K. *AHFS 97 Drug Information*; American Society of Health-System Pharmacists: Bethesda, MD, 1997; pp 2333–2342.
 132. Ebner, C. A. Cold Therapy and its Effect on Procedural Pain in Children. *Issues Compr. Pediatr. Nurs.* **1996**, *19*, 197–208.
 133. Al-Suwayeh, S. A.; Tebbett, I. R.; Wielbo, D.; Brazeau, G. A. In Vitro-In Vivo Myotoxicity of Intramuscular Liposomal Formulations. *Pharm. Res.* **1996**, *13*, 1384–1388.
 134. Brazeau, G. A.; Sciame, M.; Al-Suwayeh, S. A.; Fattal, E. Evaluation of PGLA Microsphere Size on Myotoxicity Using the Isolated Rodent Skeletal Muscle Model. *Pharm. Dev. Tech.* **1996**, *1*, 279–283.
 135. Brazeau, G. A.; Fung, H.-L. Effect of Organic Cosolvent-Induced Skeletal Muscle Damage on the Bioavailability of Intramuscular [¹⁴C]Diazepam. *J. Pharm. Sci.* **1990**, *79*, 773–777.
 136. Hoover, D. M.; Gardner, J. B.; Timmerman, T. L.; Klepfer, J. A. Laska, D. A.; White, S. L.; McCrath, J. P.; Buening, M. K.; Williams, P. D. Comparison of In Vitro and In Vivo Models to Assess Venous Irritation of Parenteral Antibiotics. *Fundamen. Appl. Toxicol.* **1990**, *14*, 589–597.
 137. Chellman, G. J.; Faurot, G. F.; Lollini, L. O.; McCullough, T. E. Rat Paw Lick/Muscle Irritation Model for Evaluation of Parenteral Formulations for Pain-on-injection and Muscle Damage. *Fundamen. Appl. Toxicol.* **1990**, *15*, 697–709.
 138. Marcek, J. M.; Seaman, W. J.; Weaver, R. J. A Novel Approach for the Determination of the Pain-producing Potential of Intravenously Injected Substances in the Conscious Rat. *Pharm. Res.* **1992**, *9*, 182–186.
 139. Sweetana, S.; Akers, M. J. Solubility Principles and Practices for Parenteral Drug Dosage Form Development. *PDA J. Pharm. Sci. Sci.* **1996**, *50*, 330–342.

Acknowledgments

We would like to thank Ms. Patricia Khan and Ms. Deborah McEdward for technical assistance in the preparation of the manuscript.

JS970315L